Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 2
1946 1
1948 6
1949 2
1950 2
1951 1
1952 1
1953 1
1955 1
1956 1
1957 3
1958 4
1959 3
1960 6
1961 3
1962 2
1963 5
1964 4
1965 6
1966 5
1967 9
1968 3
1969 6
1970 7
1971 7
1972 9
1973 6
1974 8
1975 17
1976 15
1977 31
1978 24
1979 27
1980 46
1981 28
1982 34
1983 60
1984 58
1985 59
1986 60
1987 57
1988 88
1989 89
1990 83
1991 73
1992 95
1993 98
1994 81
1995 89
1996 102
1997 129
1998 141
1999 103
2000 131
2001 144
2002 140
2003 185
2004 165
2005 190
2006 185
2007 181
2008 204
2009 183
2010 196
2011 260
2012 287
2013 315
2014 304
2015 294
2016 380
2017 394
2018 400
2019 452
2020 527
2021 600
2022 586
2023 271

Text availability

Article attribute

Article type

Publication date

Search Results

7,989 results

Results by year

Filters applied: . Clear all
Page 1
Stereotactic radiosurgery for medium and large uveal melanoma with a non-invasive eye immobilization device, a single institutional case series.
Tsui MC, Chia-Hsien Cheng J, Lin CP. Tsui MC, et al. J Formos Med Assoc. 2023 May 29:S0929-6646(23)00139-0. doi: 10.1016/j.jfma.2023.04.013. Online ahead of print. J Formos Med Assoc. 2023. PMID: 37258323
PURPOSE: To investigate the treatment outcome, visual outcome, and adverse effects of five-fraction stereotactic radiosurgery (SRS) to medium- and large-sized uveal melanoma with a non-invasive eye immobilization device. METHODS: Medical records of 14 patients with …
PURPOSE: To investigate the treatment outcome, visual outcome, and adverse effects of five-fraction stereotactic radiosurgery (SRS) to mediu …
Single-masked Randomized Phase II Study Assessing Two Forms of Hypofractionated Proton Therapy in Patients with Large Choroidal Melanomas.
Thariat J, Mathis T, Pace-Loscos T, Peyrichon ML, Maschi C, Rosier L, Nguyen M, Bonnin N, Aloi D, Gastaud L, Gaucher D, Caujolle JP, Château Y, Herault J. Thariat J, et al. Int J Radiat Oncol Biol Phys. 2023 May 29:S0360-3016(23)00434-0. doi: 10.1016/j.ijrobp.2023.04.028. Online ahead of print. Int J Radiat Oncol Biol Phys. 2023. PMID: 37257661
BACKGROUND: Patients with large uveal melanomas are at major risk of liver metastases. Some patients are reluctant to undergo the standard treatment, i.e., immediate enucleation. Proton therapy yields five-year local control rates and eyeball retention of >85% and 20% i …
BACKGROUND: Patients with large uveal melanomas are at major risk of liver metastases. Some patients are reluctant to undergo the sta …
MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma.
Tang MCY, Ferreira TA, Marinkovic M, Jaarsma-Coes MG, Klaassen L, Vu THK, Creutzberg CL, Rodrigues MF, Horeweg N, Klaver YLB, Rasch CRN, Luyten GPM, Beenakker JM. Tang MCY, et al. Neuroradiology. 2023 May 30. doi: 10.1007/s00234-023-03166-1. Online ahead of print. Neuroradiology. 2023. PMID: 37249621
PURPOSE: MRI is increasingly used in the diagnosis and therapy planning of uveal melanoma (UM). In this prospective cohort study, we assessed the radiological characteristics, in terms of anatomical and functional imaging, of UM after ruthenium-106 plaque brachyther …
PURPOSE: MRI is increasingly used in the diagnosis and therapy planning of uveal melanoma (UM). In this prospective cohort stu …
[The Role and Significance of Hepatic Environmental Cells in Tumor Metastatic Colonization to Liver].
Jin B, Zhang YY, Pan JX. Jin B, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 May;54(3):469-474. doi: 10.12182/20230560301. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37248570 Review. Chinese.
Liver is a common site for metastasis. The pattern of metastasis in uveal melanoma, colorectal carcinoma, and pancreatic ductal adenocarcinoma shows organ-tropism for liver. ...
Liver is a common site for metastasis. The pattern of metastasis in uveal melanoma, colorectal carcinoma, and pancreatic ducta …
Ferroptosis induced by DCPS depletion diminishes hepatic metastasis in uveal melanoma.
Jin B, Yang L, Ye Q, Pan J. Jin B, et al. Biochem Pharmacol. 2023 May 26:115625. doi: 10.1016/j.bcp.2023.115625. Online ahead of print. Biochem Pharmacol. 2023. PMID: 37245534
Hepatic metastasis develops in 50% of uveal melanoma (UM) patients with scarcely effective treatment resulting in lethality. ...
Hepatic metastasis develops in 50% of uveal melanoma (UM) patients with scarcely effective treatment resulting in lethality. . …
Differences and Similarities in Epidemiology and Risk Factors for Cutaneous and Uveal Melanoma.
Brănișteanu DE, Porumb-Andrese E, Stărică A, Munteanu AC, Toader MP, Zemba M, Porumb V, Cozmin M, Moraru AD, Nicolescu AC, Brănișteanu DC. Brănișteanu DE, et al. Medicina (Kaunas). 2023 May 14;59(5):943. doi: 10.3390/medicina59050943. Medicina (Kaunas). 2023. PMID: 37241175 Free PMC article. Review.
Both cutaneous melanoma (CM) and uveal melanoma (UM) represent important causes of morbidity and mortality. ...Uveal melanoma is a rare condition but is the most prevalent primary intra-ocular malignant tumor in adults. ...
Both cutaneous melanoma (CM) and uveal melanoma (UM) represent important causes of morbidity and mortality. ...Uveal …
Microphthalmia-Associated Transcription Factor: A Differentiation Marker in Uveal Melanoma.
Gelmi MC, Verdijk RM, Houtzagers LE, van der Velden PA, Kroes WGM, Luyten GPM, Vu THK, Jager MJ. Gelmi MC, et al. Int J Mol Sci. 2023 May 16;24(10):8861. doi: 10.3390/ijms24108861. Int J Mol Sci. 2023. PMID: 37240204 Free PMC article.
Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development. In cutaneous melanoma, MITF loss has been linked to an increased expression of stem cell markers, a shift in epithelial-to-mesenchymal transition (E …
Microphthalmia-associated transcription factor (MITF) is an important regulator of melanogenesis and melanocyte development. In cutaneous …
Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma.
Goesmann L, Refaian N, Bosch JJ, Heindl LM. Goesmann L, et al. Biology (Basel). 2023 May 19;12(5):738. doi: 10.3390/biology12050738. Biology (Basel). 2023. PMID: 37237550 Free PMC article.
Uveal melanoma (UM) is a highly malignant tumor of the eye. Metastatic spread of UM occurs almost exclusively via blood vessels and is of tremendous interest, as half of the patients with uveal melanoma die of metastasis in the long run. ...
Uveal melanoma (UM) is a highly malignant tumor of the eye. Metastatic spread of UM occurs almost exclusively via blood vessel …
Corneal Perforation as a Rare and Late Manifestation of Choroidal Melanoma.
Berger T, Flockerzi F, Löw U, Flockerzi E, Aljundi W, Abdin A, Daas L, Seitz B. Berger T, et al. Klin Monbl Augenheilkd. 2023 May 24. doi: 10.1055/a-2069-2354. Online ahead of print. Klin Monbl Augenheilkd. 2023. PMID: 37224861 English.
RESULTS: The histopathological examination revealed choroidal melanoma with epithelioid and spindle cell components at the posterior pole, which was positive for Melan-A, Human Melanoma Black 45 (HMB45), BAP1, and SOX10. ...CONCLUSION: Corneal perforation sho …
RESULTS: The histopathological examination revealed choroidal melanoma with epithelioid and spindle cell components at the pos …
Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.
Champiat S, Salaün H, Lucibello F, Scoazec JY, Besse B, Lalanne AI, Rouleau E, Metzger N, Saint-Ghislain M, Ryckewaert T, Gardrat S, Barnhill R, Cassoux N, Stern MH, Lantz O, de Koning L, Marabelle A, Rodrigues M. Champiat S, et al. JCO Precis Oncol. 2023 May;7:e2200363. doi: 10.1200/PO.22.00363. JCO Precis Oncol. 2023. PMID: 37224427 No abstract available.
7,989 results